ScoreComparison
Why is Lineage Cell Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Lineage Cell Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
52.80%
EBIT Growth (5y)
5.37%
EBIT to Interest (avg)
-28.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
58.70%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.95
EV to EBIT
-5.04
EV to EBITDA
-5.19
EV to Capital Employed
3.33
EV to Sales
11.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-66.01%
ROE (Latest)
-26.06%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET SALES(HY)
At USD 4.27 MM has Grown at 49.61%
RAW MATERIAL COST(Y)
Fallen by -6.55% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -82.95 %
DEBTORS TURNOVER RATIO(HY)
Highest at 44.46 times
PRE-TAX PROFIT(Q)
Highest at USD -2.78 MM
NET PROFIT(Q)
Highest at USD -2.88 MM
-3What is not working for the Company
ROCE(HY)
Lowest at -70.12%
EPS(Q)
Lowest at USD -0.13
Here's what is working for Lineage Cell Therapeutics, Inc.
Net Sales
At USD 4.27 MM has Grown at 49.61%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
Highest at USD -2.78 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -2.78 MM has Grown at 45.96%
over average net sales of the previous four periods of USD -5.15 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -2.88 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -2.88 MM has Grown at 44.12%
over average net sales of the previous four periods of USD -5.16 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -82.95 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 44.46 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.55% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lineage Cell Therapeutics, Inc.
EPS
Lowest at USD -0.13
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
